Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR2988)
Drug Name
Napitane mesilate
Synonyms
A-75200; ABT-200; Napitane mesilate < Prop INNM; Rac-1-[5,6-(Methylenedioxy)-1,2,3,4-tetrahydronaphth-1(R*)-ylmethyl]-3(R*)-phenylpyrrolidine methanesulfonate; Rac-3(R*)-Phenyl-1-[6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6(R*)-ylmethyl]pyrrolidine methanesulfonate
Indication Major depressive disorder [ICD11: 6A70-6A7Z] Discontinued in Phase 2 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 335.4 Topological Polar Surface Area 21.7
Heavy Atom Count 25 Rotatable Bond Count 3
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 3
Cross-matching ID
PubChem CID
60932
TTD Drug ID
D06KOL
Formula
C22H25NO2
Canonical SMILES
C1CC(C2=C(C1)C3=C(C=C2)OCO3)CN4CCC(C4)C5=CC=CC=C5
InChI
InChI=1S/C22H25NO2/c1-2-5-16(6-3-1)17-11-12-23(13-17)14-18-7-4-8-20-19(18)9-10-21-22(20)25-15-24-21/h1-3,5-6,9-10,17-18H,4,7-8,11-15H2
InChIKey
HAEPGZUGYMHCJE-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Napitane mesilate Metabolite M1 DM017797 N. A. Oxidation - Oxidation 1 [2]
Napitane mesilate Metabolite M10 DM017803 N. A. Multi-steps Reaction - Glucuronidation; sulfation 2 [2]
Napitane mesilate Metabolite M2 DM017801 N. A. Multi-steps Reaction - Glucuronidation; sulfation 2 [2]
Napitane mesilate Metabolite M3 DM017802 N. A. Conjugation - Glucuronidation 2 [2]
Napitane mesilate Metabolite M4 DM017798 N. A. Unclear - Unclear 2 [2]
Napitane mesilate Metabolite M6 DM015894
15029958
Unclear - Unclear 2 [2]
Napitane mesilate Metabolite M8 DM017805 N. A. Conjugation - Sulfation 2 [2]
Napitane mesilate Metabolite M9 DM017804 N. A. Conjugation - Sulfation 2 [2]
Napitane mesilate Metabolite M5 DM017799 N. A. Conjugation - Glucuronidation 3 [2]
Napitane mesilate Metabolite M7 DM017800 N. A. Conjugation - Sulfation 3 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR009336 Napitane mesilate Napitane mesilate Metabolite M1 Oxidation - Oxidation Unclear [2]
MR009337 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M4 Unclear - Unclear COMT [2]
MR009339 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M6 Unclear - Unclear COMT [2]
MR009341 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M2 Multi-steps Reaction - Glucuronidation; sulfation Unclear [2]
MR009342 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M3 Conjugation - Glucuronidation Unclear [2]
MR009343 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M10 Multi-steps Reaction - Glucuronidation; sulfation Unclear [2]
MR009344 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M9 Conjugation - Sulfation Unclear [2]
MR009345 Napitane mesilate Metabolite M1 Napitane mesilate Metabolite M8 Conjugation - Sulfation Unclear [2]
MR009338 Napitane mesilate Metabolite M4 Napitane mesilate Metabolite M5 Conjugation - Glucuronidation Unclear [2]
MR009340 Napitane mesilate Metabolite M6 Napitane mesilate Metabolite M7 Conjugation - Sulfation Unclear [2]
⏷ Show the Full List of 10 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Catechol O-methyltransferase (COMT) DME0043 Homo sapiens
COMT_HUMAN
2.1.1.6
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A7 (CYP3A7) DME0015 Homo sapiens
CP3A7_HUMAN
1.14.14.1
[3]
References
1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005107)
2 Implication of P450-metabolite complex formation in the nonlinear pharmacokinetics and metabolic fate of (+/-)-(1'R*,3R*)-3-phenyl-1-[(1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200) in dogs
3 Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform. Front Pharmacol. 2022 Jul 1;13:899536. doi: 10.3389/fphar.2022.899536.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.